

Media Release

Zug, 18 May 2022

Ad hoc announcement pursuant to Art. 53 Listing Rules

Publication of Annual Report 2021/2022 and Invitation to the Ordinary Shareholders' Meeting

The invitation to the 21st Ordinary Shareholders' Meeting on 10 June 2022 has been sent to the shareholders of HBM Healthcare Investments today.

In accordance with the Ordinance on Measures to Combat the Coronavirus, issued by the Swiss Federal Council, the shareholders are not permitted to participate in person. All shareholders are kindly asked to exercise their rights exclusively through the independent proxy by way of written or electronic instruction and power of attorney.


The detailed invitation with all motions of the Board of Directors is displayed on the Company's website www.hbmhealthcare.com/en/investors/shareholders-meeting.

Agenda for the 21st Ordinary Shareholders' Meeting on 10 June 2022

1. Statutory financial statements and group financial statements 2021/2022; reports of the auditors
2. Discharge from liability of the members of the Board of Directors and Management
3. Appropriation of results
 - Appropriation of disposable profit of CHF 327'937'326.
4. Elections regarding the Board of Directors
 - Re-elections of the Chairman and of the Members of the Board of Directors
 - Re-elections of the Members of the Compensation Committee
5. Compensation to the Board of Directors and to the Management
6. Appointment of auditors
7. Appointment of independent proxy-holder
8. Reduction of share capital: partial payback of nominal value
 - Cash distribution to shareholders of CHF 9.70 per share through nominal value repayment
9. Approval of a new share buy-back programme and capital reduction in principle
10. Miscellaneous

HBM Healthcare Investments also published today its Annual Report 2021/2022 on the Company's website www.hbmhealthcare.com/en/investors/financial-reports.

HBM Healthcare Investments Ltd.

Bundesplatz 1 CH-6300 Zug | Phone: +41 41 710 75 77 | info@hbmhealthcare.com | www.hbmhealthcare.com
Follow us on Twitter:  @HbmHealthcare

Contact

For further information, please contact Dr. Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

The publication is for information purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe for securities. This news release does not constitute a prospectus within the meaning of Art. 35ff FinSA, or securities prospectus in the sense of the German securities prospectus law. This news release and the information contained therein is not intended for distribution to the United States of America (USA) or within the USA and may not be distributed or forwarded to US persons (including legal persons) or to publications with a general distribution in the USA. This news release is not an offer or solicitation to buy securities in the United States. HBM Healthcare Investments AG's securities were not issued in accordance with the U.S. U.S. securities laws, and may not be sold, offered for sale, or delivered in the U.S. or to U.S. individuals without prior registration or without a registration exemption. Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible or liable for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions.